Search Within

Mikhail Roshal

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (33)
  2. Meeting Abstract (31)
  3. Research Letter (3)
  4. Correspondence (1)
Groups
  1. Department of Pathology and Laboratory Medicine (68)
  2. Epidemiology and Biostatistics (68)
  3. Center for Hematologic Malignancies (66)
  4. Department of Medicine (65)
  5. Hematologic Malignancies, Division of (65)
  6. Biostatistics Service (53)

More Groups

People
  1. Sean Devlin (31)
  2. Sergio Giralt (30)
  3. Maria Arcila (27)
  4. Ahmet Dogan (24)
  5. Ross Levine (24)
  6. Martin Tallman (22)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (9)
  4. 2022 (10)
  5. 2021 (13)
  6. 2020 (8)

More Years

Publications
  1. Blood (30)
  2. Blood Advances (7)
  3. American Journal of Hematology (3)
  4. Leukemia and Lymphoma (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Clinical Lymphoma, Myeloma and Leukemia (2)

More Publications

Publishers
  1. American Society of Hematology (37)
  2. Elsevier Inc. (5)
  3. American Association for Cancer Research (4)
  4. Nature Publishing Group (4)
  5. John Wiley & Sons, Inc. (3)
  6. Taylor & Francis Group (3)

More Publishers

Results (68)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
    Journal Article

    Xiao, W.; Chan, A.; Waarts, M. R.; Mishra, T.; Liu, Y.; Cai, S. F.; Yao, J.; Gao, Q.; Bowman, R. L.; Koche, R. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy
    Research Letter

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Arcila, M.; Roshal, M.; Zhang, Y.; Famulare, C. A.; Goldberg, A. D.; Cai, S. F.; Dunbar, A.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
    Journal Article

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J.; King, A. C.; Daniyan, A. F.; Famulare, C.; Cuello, B. M.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia
    Journal Article

    Geyer, M. B.; Ritchie, E. K.; Rao, A. V.; Vemuri, S.; Flynn, J.; Hsu, M.; Devlin, S. M.; Roshal, M.; Gao, Q.; Shukla, M.; more...
    Haematologica (2021)

    Fulltext@MSK | Save
  • Venetoclax therapy for relapsed and treatment refractory AML: Clinical outcomes and molecular predictors
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; Chan, A.; Xiao, W.; Glass, J. L.; King, A. C.; Daniyan, A.; Famulare, C.; Cuello, B. M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Clinical outcomes of acute myeloid leukemia patients bridged to allogeneic stem cell transplant by venetoclax combination therapy
    Meeting Abstract

    Stahl, M.; Menghrajani, K.; Derkach, A.; DeWolf, S.; Ruiz, J. D.; Ponce, D. M.; Shaffer, B. C.; Tamari, R.; Young, J. W.; Barker, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save